Today: 25 January 2026
Subscribe
Browse Category

NASDAQ:RVMD News 7 January 2026 - 8 January 2026

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

New York, Jan 7, 2026, 18:35 EST — After-hours AbbVie (ABBV.N) shares were down about 1% at $231.11 in after-hours trading on Wednesday after the drugmaker denied a Wall Street Journal report that it was in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), saying it “is not in discussions with Revolution Medicines.” The stock had closed up 4.2%…
8 January 2026
······
AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

New York, Jan 7, 2026, 16:14 (EST) AbbVie (ABBV.N) is in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Revolution shares jumped nearly 30% after the report, while AbbVie rose more than 5%. Reuters For AbbVie, a takeover would also sharpen its push to add new…
7 January 2026
····
1 2

Stock Market Today

  • PAL GROUP Holdings Boosts Year-End Dividend to ¥40, Enhancing Shareholder Value
    January 25, 2026, 9:48 AM EST. PAL GROUP Holdings (TSE:2726) announced a 33% increase in its year-end dividend to ¥40 per share, effective May 27, 2026, reflecting stronger sales and profits for the nine months ended November 2025. The move aims to reinforce the company's commitment to stable, profit-linked shareholder returns amid ongoing governance changes, including adjustments to directors and auditors post board meeting. While the dividend hike partially offsets recent share price weakness, key challenges remain, such as maintaining margins and managing leadership transition. Market analysts highlight a nuanced risk-reward balance, with fair value estimates ranging near ¥2,500, suggesting the stock may still be undervalued by 32% despite governance concerns. Investors are advised to monitor capital allocation and board independence as the company navigates these changes.
Go toTop